Hui Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hui Zhao has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Yun Xu
Department of Neurology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
15 shared publications Renyuan Liu
Department of Neurology, The State Key Laboratory of Pharmaceutical Biotechnology, Affiliated Drum Tower Hospital of Medical School, Nanjing University, Nanjing, P. R. China
7 shared publicationsRuomeng Qin
Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital
7 shared publications- Feng Bai
Department of Neurology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
6 shared publications Haifeng Chen
Department of Neurology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
6 shared publicationsYun Xu
Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, Jiangsu China
6 shared publications
Latest Publications
- 22 October 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (11) , 677
Dynamic long-term modulation of cognition, brain structure and covariance networks in mild cognitive impairment due to AD by donepezil: A 36-month longitudinal study
Background Whether donepezil exerts long-term efficacy in mitigating cognitive decline, preserving brain structure, and restoring impaired structural covariance networks in patients with mild cognitive impairment due to Alzheimer′s disease (AD-MCI) remains controversial. Objective This study aimed to characterize the longitudinal dynamic alterations in cognition, brain morphology, and structural covariance network topology in AD-MCI patients receiving continuous 36-month donepezil treatment, thereby elucidating the long-term modulatory effects of donepezil on AD progression. Methods Cross-sectional analysis included 92 normal controls (NC) and 107 AD-MCI patients to identify baseline abnormalitiesin cognitive performance, brain morphological parameters, global topological features, and nodal metrics of individual gray matter covariance networks. Subsequently, 35 AD-MCI patients who completed 36-month continuous donepezil treatment were retrospectively enrolled to explore the therapeutic modulation of donepezil on the aforementioned abnormal indicators. Linear and piecewise linear mixed-effects models were employed to quantify longitudinal changes. Results AD-MCI patients showed left hippocampus (including subfields) atrophy and widespread structural covariance network impairment at baseline. During treatment, significant time main effects were observed in MMSE scores and the volume of the left hippocampus and multiple subfields, both of which continued to show progressive decline, with accelerated deterioration between 12 and 18 months. Global topological metrics stabilized after initial short-term improvement, while right hippocampus nodal metrics were significantly enhanced. Conclusions Donepezil treatment in AD-MCI patients represents a dynamic therapeutic process: it elicits transient short-term improvement of global brain network topology but confers only modest long-term benefits, with insufficient evidence supporting sustained, impactful neuroprotective effects. This study provides novel multi-level longitudinal evidence describing the neuroimaging changes underlying donepezil's modulation of AD progression.
- 22 October 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (11) , 677
Dynamic long-term modulation of cognition, brain structure and covariance networks in mild cognitive impairment due to AD by donepezil: A 36-month longitudinal study
Background Whether donepezil exerts long-term efficacy in mitigating cognitive decline, preserving brain structure, and restoring impaired structural covariance networks in patients with mild cognitive impairment due to Alzheimer′s disease (AD-MCI) remains controversial. Objective This study aimed to characterize the longitudinal dynamic alterations in cognition, brain morphology, and structural covariance network topology in AD-MCI patients receiving continuous 36-month donepezil treatment, thereby elucidating the long-term modulatory effects of donepezil on AD progression. Methods Cross-sectional analysis included 92 normal controls (NC) and 107 AD-MCI patients to identify baseline abnormalitiesin cognitive performance, brain morphological parameters, global topological features, and nodal metrics of individual gray matter covariance networks. Subsequently, 35 AD-MCI patients who completed 36-month continuous donepezil treatment were retrospectively enrolled to explore the therapeutic modulation of donepezil on the aforementioned abnormal indicators. Linear and piecewise linear mixed-effects models were employed to quantify longitudinal changes. Results AD-MCI patients showed left hippocampus (including subfields) atrophy and widespread structural covariance network impairment at baseline. During treatment, significant time main effects were observed in MMSE scores and the volume of the left hippocampus and multiple subfields, both of which continued to show progressive decline, with accelerated deterioration between 12 and 18 months. Global topological metrics stabilized after initial short-term improvement, while right hippocampus nodal metrics were significantly enhanced. Conclusions Donepezil treatment in AD-MCI patients represents a dynamic therapeutic process: it elicits transient short-term improvement of global brain network topology but confers only modest long-term benefits, with insufficient evidence supporting sustained, impactful neuroprotective effects. This study provides novel multi-level longitudinal evidence describing the neuroimaging changes underlying donepezil's modulation of AD progression.
- Open Access
- 14 March 2026
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 13 (5) , 100533
Donanemab therapy in Alzheimer’s disease with mild cognitive impairment: Convergent amyloid, tau, and plasma biomarker normalization with cognitive improvement
- 14 March 2026
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 13 (5) , 100533
Open AccessDonanemab therapy in Alzheimer’s disease with mild cognitive impairment: Convergent amyloid, tau, and plasma biomarker normalization with cognitive improvement
- Open Access
- 25 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S5) , e101524
Protocol for a multicenter, prospective, real‐world study: Lecanemab in patients with early Alzheimer's disease(LEAD) in China
Background: Lecanemab, a humanized IgG1 monoclonal antibody that targets soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid reduction and slowing of clinical decline in early Alzheimer's disease(AD) and received its approval for this indication in the USA 2023 and China 2024. However, reports published of real‐world data on this therapy are still very limited, espcially in China. LEAD is an investigator‐ led, multicenter, prospective, real‐world study in 20 hospitals in Jiangsu Province, China. The primary objective was to assess the effectiveness of lecanemab under real‐world clinical practice in early Alzheimer's diseasepatients in China. The secondary objectives included evaluating the safety of lecanemab in Chinese patients. Method: This prospective cohort trial included early AD (mild cognitive impairment or mild dementia due to AD) patients having an indication for lecanemab. Each participant had evidence of amyloid on positronemission tomography (PET) or by cerebrospinal fluid testing. Baseline data on demographics, medical history, cognitive score, plasma biomarkers, Apoe and MR indicators were assessed and a treatment with intravenous lecanemab (10 mg per kilogram of body weight each 2 weeks) was started. The patients will be followed up, attend safety visits, provide blood samples to measure AD biomarkers at months 3, 6 and 12. AD blood biomarkers was detected using chemiluminescence. All cognitive assessments will be repeated at month 6 and 12, structural MR will be noted at month 1,1.5,3.5 and 6. The last study visit will be at month 12, when all baseline measurements will be repeated. The study was approved by the Drum Tower Hospital Research Ethics Committee (2024‐746‐01). Result: This study is onging, 90 subjects have been recruited. Currently in the data extraction phase. Baseline data collection of the subjects is shown in Table 1. All patients will complete 6 months of treatment in July 2025. Updated result will be available for the conference. Conclusion: The LEAD project is a multi‐center, real‐world study that will determine the therapeutic efficacy of lecanemab in alleviating clinical symptoms and pathological aspects in Alzheimer's disease patients in Jiangsu, China, as well as monitor adverse effects, in order to assist the treatment of more Asian AD patients.
- 25 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S5) , e101524
Open AccessProtocol for a multicenter, prospective, real‐world study: Lecanemab in patients with early Alzheimer's disease(LEAD) in China
Background: Lecanemab, a humanized IgG1 monoclonal antibody that targets soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid reduction and slowing of clinical decline in early Alzheimer's disease(AD) and received its approval for this indication in the USA 2023 and China 2024. However, reports published of real‐world data on this therapy are still very limited, espcially in China. LEAD is an investigator‐ led, multicenter, prospective, real‐world study in 20 hospitals in Jiangsu Province, China. The primary objective was to assess the effectiveness of lecanemab under real‐world clinical practice in early Alzheimer's diseasepatients in China. The secondary objectives included evaluating the safety of lecanemab in Chinese patients. Method: This prospective cohort trial included early AD (mild cognitive impairment or mild dementia due to AD) patients having an indication for lecanemab. Each participant had evidence of amyloid on positronemission tomography (PET) or by cerebrospinal fluid testing. Baseline data on demographics, medical history, cognitive score, plasma biomarkers, Apoe and MR indicators were assessed and a treatment with intravenous lecanemab (10 mg per kilogram of body weight each 2 weeks) was started. The patients will be followed up, attend safety visits, provide blood samples to measure AD biomarkers at months 3, 6 and 12. AD blood biomarkers was detected using chemiluminescence. All cognitive assessments will be repeated at month 6 and 12, structural MR will be noted at month 1,1.5,3.5 and 6. The last study visit will be at month 12, when all baseline measurements will be repeated. The study was approved by the Drum Tower Hospital Research Ethics Committee (2024‐746‐01). Result: This study is onging, 90 subjects have been recruited. Currently in the data extraction phase. Baseline data collection of the subjects is shown in Table 1. All patients will complete 6 months of treatment in July 2025. Updated result will be available for the conference. Conclusion: The LEAD project is a multi‐center, real‐world study that will determine the therapeutic efficacy of lecanemab in alleviating clinical symptoms and pathological aspects in Alzheimer's disease patients in Jiangsu, China, as well as monitor adverse effects, in order to assist the treatment of more Asian AD patients.
- Open Access
- 24 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S2) , e100047
The effect of APOEε4 on the functional gradient of the brain default network in Alzheimer's disease and its relationship with cognitive functions
Background: APOEε4 allele has an increased risk of Alzheimer's disease(AD) compared to others. Functional connectivity gradients are a novel hierarchical design of functional connectivity patterns in brain networks that captures the spatial correlations between connectivity patterns in various locations. The aim of this research is how the APOE ε4 affects the functional connectivity gradients of the default mode network (DMN) in AD and how it correlates with cognitive function. Method: From September 2022 to September 2024, 271 subjects were recruited from memory clinic of Drum Tower Hospital, Nanjing University Medical School. The study included 108 healthy controls(HC) APOE ε4 non‐carriers, 25 HC APOE ε4 carriers, 81 AD APOE ε4 non‐carriers, and 57 AD APOE ε4 carriers. All individules underwent cognitive function testing, blood test of AD biomarkers and resting‐state functional magnetic resonance imaging (rs‐fMRI). A two‐factor ANOVA and Correlation tests were utilized to examine the relationship between APOE ε4, functional gradients and cognitive function in four groups. Intermediary analysis was used to investigate the relationship between the DMN functional gradient and blood AD biomarkers. Result: After controlling for sex, age, and years of education, there was an interaction between the presence of the APOE ε4 gene and the functional gradient in the right temporal lobe of DMN in two groups; In APOE ε4 non‐carriers, the DMN functional gradient was significantly higher in AD compared to HC ( p < 0.001), while in APOE ε4 carriers it was significantly lower in AD ( p = 0.031); Among AD subjects, APOE‐ε4 carriers showed a significant decrease in the default network functional gradient compared to non‐carriers ( p <0.001); APOE‐ε4 carriers showed a positive correlation between DMN functional gradient in the right temporal lobe and several ognitive domains; Mediation analyses revealed that AD markers affect DMN resting‐state functional connectivity by altering DMN functional gradients. Conclusion: The APOEε4 gene impacts the functional connectivity gradient of the default network, especially in the right temporal lobe in AD patients. They are more likely than non‐carriers to experience functional network gradient derangement, which is linked to cognitive deterioration. This effect may be related to blood AD markers altering the DMN functional gradient affecting DMN resting‐state functional connectivity.
- 24 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S2) , e100047
Open AccessThe effect of APOEε4 on the functional gradient of the brain default network in Alzheimer's disease and its relationship with cognitive functions
Background: APOEε4 allele has an increased risk of Alzheimer's disease(AD) compared to others. Functional connectivity gradients are a novel hierarchical design of functional connectivity patterns in brain networks that captures the spatial correlations between connectivity patterns in various locations. The aim of this research is how the APOE ε4 affects the functional connectivity gradients of the default mode network (DMN) in AD and how it correlates with cognitive function. Method: From September 2022 to September 2024, 271 subjects were recruited from memory clinic of Drum Tower Hospital, Nanjing University Medical School. The study included 108 healthy controls(HC) APOE ε4 non‐carriers, 25 HC APOE ε4 carriers, 81 AD APOE ε4 non‐carriers, and 57 AD APOE ε4 carriers. All individules underwent cognitive function testing, blood test of AD biomarkers and resting‐state functional magnetic resonance imaging (rs‐fMRI). A two‐factor ANOVA and Correlation tests were utilized to examine the relationship between APOE ε4, functional gradients and cognitive function in four groups. Intermediary analysis was used to investigate the relationship between the DMN functional gradient and blood AD biomarkers. Result: After controlling for sex, age, and years of education, there was an interaction between the presence of the APOE ε4 gene and the functional gradient in the right temporal lobe of DMN in two groups; In APOE ε4 non‐carriers, the DMN functional gradient was significantly higher in AD compared to HC ( p < 0.001), while in APOE ε4 carriers it was significantly lower in AD ( p = 0.031); Among AD subjects, APOE‐ε4 carriers showed a significant decrease in the default network functional gradient compared to non‐carriers ( p <0.001); APOE‐ε4 carriers showed a positive correlation between DMN functional gradient in the right temporal lobe and several ognitive domains; Mediation analyses revealed that AD markers affect DMN resting‐state functional connectivity by altering DMN functional gradients. Conclusion: The APOEε4 gene impacts the functional connectivity gradient of the default network, especially in the right temporal lobe in AD patients. They are more likely than non‐carriers to experience functional network gradient derangement, which is linked to cognitive deterioration. This effect may be related to blood AD markers altering the DMN functional gradient affecting DMN resting‐state functional connectivity.
- 27 October 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 108 (4) , 1726-1737
Alzheimer's disease pathogenesis and the role of APOE ε4 in remodeling functional gradients of the default mode network
Background: Alzheimer's disease (AD) involves Aβ and tau pathology, initiating years before symptoms. the apolipoprotein E ε4 allele ( APOE ε4) is the major genetic risk factor, influencing neurodegeneration and functional network disruption. This study investigates how APOE ε4 modulates the default mode network (DMN)'s hierarchical organization to accelerate cognitive decline. Objective: This study aimed to elucidate how APOE ε4 accelerates AD pathological progression by altering the functional gradient hierarchy of DMN, and to evaluate the potential of DMN gradient abnormalities as an early diagnostic biomarker for AD. Methods: We enrolled 271 participants, categorized by diagnosis and APOE ε4 status. All underwent neuropsychological assessment, plasma Aβ 42/40 measurement, and resting-state functional MRI. DMN functional gradients were quantified using the BrainSpace toolbox. Statistical analyses included a 2 × 2 factorial design, mediation analysis, and correlation testing with cognitive scores. Results: A significant Group × Genotype interaction was identified in the right inferior temporal gyrus (RITG). AD patients with APOE ε4 showed the most severe gradient attenuation, while non-carrier patients exhibited compensatory elevation. The RITG gradient correlated with multiple cognitive domains exclusively in APOE ε4 carriers. Altered connectivity between the left superior frontal gyrus (LSFG) and RITG mediated the effect of Aβ burden on gradient disruption. Conclusions: APOE ε4 accelerates cognitive decline in AD by specifically disrupting the DMN functional gradient hierarchy, particularly within the right ITG. Amyloid-β deposition contributes to macro-scale DMN topological disorganization by impairing LSFG-RITG functional connectivity. DMN functional gradient mapping provides a sensitive biomarker for early AD diagnosis and a novel target for APOE ε4-targeted interventions.
- 27 October 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 108 (4) , 1726-1737
Alzheimer's disease pathogenesis and the role of APOE ε4 in remodeling functional gradients of the default mode network
Background: Alzheimer's disease (AD) involves Aβ and tau pathology, initiating years before symptoms. the apolipoprotein E ε4 allele ( APOE ε4) is the major genetic risk factor, influencing neurodegeneration and functional network disruption. This study investigates how APOE ε4 modulates the default mode network (DMN)'s hierarchical organization to accelerate cognitive decline. Objective: This study aimed to elucidate how APOE ε4 accelerates AD pathological progression by altering the functional gradient hierarchy of DMN, and to evaluate the potential of DMN gradient abnormalities as an early diagnostic biomarker for AD. Methods: We enrolled 271 participants, categorized by diagnosis and APOE ε4 status. All underwent neuropsychological assessment, plasma Aβ 42/40 measurement, and resting-state functional MRI. DMN functional gradients were quantified using the BrainSpace toolbox. Statistical analyses included a 2 × 2 factorial design, mediation analysis, and correlation testing with cognitive scores. Results: A significant Group × Genotype interaction was identified in the right inferior temporal gyrus (RITG). AD patients with APOE ε4 showed the most severe gradient attenuation, while non-carrier patients exhibited compensatory elevation. The RITG gradient correlated with multiple cognitive domains exclusively in APOE ε4 carriers. Altered connectivity between the left superior frontal gyrus (LSFG) and RITG mediated the effect of Aβ burden on gradient disruption. Conclusions: APOE ε4 accelerates cognitive decline in AD by specifically disrupting the DMN functional gradient hierarchy, particularly within the right ITG. Amyloid-β deposition contributes to macro-scale DMN topological disorganization by impairing LSFG-RITG functional connectivity. DMN functional gradient mapping provides a sensitive biomarker for early AD diagnosis and a novel target for APOE ε4-targeted interventions.
- Open Access
- 26 April 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-10
Association between high plasma p-tau181 level and gait changes in patients with mild cognitive impairment
Previous studies on gait changes in mild cognitive impairment (MCI) are inconsistent. Alzheimer’s disease (AD) plasma biomarkers, amyloid beta (Aβ) and phosphorylated-tau (p-tau), are relevant to gait disorders. This study explores gait changes in MCI and the relationship between gait performance and AD plasma biomarkers. 231 participants were recruited and stratified based on p-tau181 levels into: low p-tau181 with normal cognition (lT-NC), low p-tau181 with MCI (lT-MCI), and high p-tau181 with MCI (hT-MCI). The same cohort was subsequently stratified by Aβ42/Aβ40 levels into: high Aβ42/Aβ40 with normal cognition (hA-NC), high Aβ42/Aβ40 with MCI (hA-MCI), and low Aβ42/Aβ40 with MCI (lA-MCI). Demographic, cognitive and gait data were compared across groups. The hT-MCI and lA-MCI groups were older than the other groups. Significant differences in stride length were found between lT-NC and hT-MCI, lT-MCI and hT-MCI, but not between lT-NC and lT-MCI. Neuropsychological assessments revealed poorer performance in hT-MCI and lT-MCI groups relative to lT-NC, while global cognitive function was comparable between hT-MCI and lT-MCI groups. No such associations were observed between stride length and Aβ42/Aβ40 levels. Decreased stride length, which is generally considered to be indicative of poorer gait, was significantly associated with elevated p-tau181 levels and independent of global cognitive status. These findings highlight the potential of p-tau181 as a biomarker for tau-related motor dysfunction in MCI.
- 26 April 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-10
Open AccessAssociation between high plasma p-tau181 level and gait changes in patients with mild cognitive impairment
Previous studies on gait changes in mild cognitive impairment (MCI) are inconsistent. Alzheimer’s disease (AD) plasma biomarkers, amyloid beta (Aβ) and phosphorylated-tau (p-tau), are relevant to gait disorders. This study explores gait changes in MCI and the relationship between gait performance and AD plasma biomarkers. 231 participants were recruited and stratified based on p-tau181 levels into: low p-tau181 with normal cognition (lT-NC), low p-tau181 with MCI (lT-MCI), and high p-tau181 with MCI (hT-MCI). The same cohort was subsequently stratified by Aβ42/Aβ40 levels into: high Aβ42/Aβ40 with normal cognition (hA-NC), high Aβ42/Aβ40 with MCI (hA-MCI), and low Aβ42/Aβ40 with MCI (lA-MCI). Demographic, cognitive and gait data were compared across groups. The hT-MCI and lA-MCI groups were older than the other groups. Significant differences in stride length were found between lT-NC and hT-MCI, lT-MCI and hT-MCI, but not between lT-NC and lT-MCI. Neuropsychological assessments revealed poorer performance in hT-MCI and lT-MCI groups relative to lT-NC, while global cognitive function was comparable between hT-MCI and lT-MCI groups. No such associations were observed between stride length and Aβ42/Aβ40 levels. Decreased stride length, which is generally considered to be indicative of poorer gait, was significantly associated with elevated p-tau181 levels and independent of global cognitive status. These findings highlight the potential of p-tau181 as a biomarker for tau-related motor dysfunction in MCI.
- 28 March 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 104 (4) , 1103-1114
APOE ε4 influences the dynamic functional connectivity variability and cognitive performance in Alzheimer's disease
Background: Apolipoprotein E ( APOE ) ε4 is the most significant genetic risk factor for sporadic Alzheimer's disease (AD). However, its impact on the dynamic changes in resting-state functional connectivity (FC), particularly concerning network formation, interaction, and dissolution over time, remains largely unexplored in AD. Objective: This study aims to explore the effect of APOE ε4 on dynamic FC (dFC) variability and cognitive performance in AD. Methods: We analyzed the dFC of AD patients, comparing APOE ε4 carriers (n = 33) with non-carriers (n = 41). The whole-brain dFC was assessed by calculating dynamic fractional amplitude of low-frequency fluctuations (dfALFF) and dynamic regional homogeneity (dReHo). To further explore the relationship between cognitive function and dFC in AD patients, we conducted a correlation analysis. Mediation analysis was also performed to determine whether dFC mediates the link between the APOE ε4 and cognitive decline in AD patients. Results: AD patients carrying the APOE ε4 exhibited more severe cognitive impairment, along with reduced dReHo and dfALFF in both the left and right posterior cerebellar lobes. In these carriers, the dFC analysis showed lower dFC between the left posterior cerebellar lobe and the left middle temporal gyrus, which was positively correlated with executive function and information processing speed. Additionally, mediation analysis indicated that APOE ε4 influences dFC in this brain region, contributing to executive dysfunction in AD. Conclusions: These findings offer preliminary evidence that APOE ε4 modulates fluctuating communication within the cerebellar lobe and the dFC between the cerebellar lobe and the temporal gyrus in AD.
- 28 March 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 104 (4) , 1103-1114
APOE ε4 influences the dynamic functional connectivity variability and cognitive performance in Alzheimer's disease
Background: Apolipoprotein E ( APOE ) ε4 is the most significant genetic risk factor for sporadic Alzheimer's disease (AD). However, its impact on the dynamic changes in resting-state functional connectivity (FC), particularly concerning network formation, interaction, and dissolution over time, remains largely unexplored in AD. Objective: This study aims to explore the effect of APOE ε4 on dynamic FC (dFC) variability and cognitive performance in AD. Methods: We analyzed the dFC of AD patients, comparing APOE ε4 carriers (n = 33) with non-carriers (n = 41). The whole-brain dFC was assessed by calculating dynamic fractional amplitude of low-frequency fluctuations (dfALFF) and dynamic regional homogeneity (dReHo). To further explore the relationship between cognitive function and dFC in AD patients, we conducted a correlation analysis. Mediation analysis was also performed to determine whether dFC mediates the link between the APOE ε4 and cognitive decline in AD patients. Results: AD patients carrying the APOE ε4 exhibited more severe cognitive impairment, along with reduced dReHo and dfALFF in both the left and right posterior cerebellar lobes. In these carriers, the dFC analysis showed lower dFC between the left posterior cerebellar lobe and the left middle temporal gyrus, which was positively correlated with executive function and information processing speed. Additionally, mediation analysis indicated that APOE ε4 influences dFC in this brain region, contributing to executive dysfunction in AD. Conclusions: These findings offer preliminary evidence that APOE ε4 modulates fluctuating communication within the cerebellar lobe and the dFC between the cerebellar lobe and the temporal gyrus in AD.
- Open Access
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S2) , e084078
Correlation between alterations in resting‐state functional alterations of brain and cerebrospinal fluid pathological markers in patients with Alzheimer's disease
Background: The aim of this study was to explore the correlation between brain functional alterations and cerebrospinal fluid (CSF) pathological biomarkers in Alzheimer's disease (AD) patients.Method: A total of 39 individuals were recruited, including 23 AD patients and 16 control subjects. All subjects underwent a battery of neuropsychological examinations, CSF measurement and multimodal magnetic resonance imaging scans. Independent component analysis was used to investigate the variations of functional connectivity (FC) between the two groups by utilizing the resting‐sate functional MRI (RS‐fMRI) data. Differences in ALFF and ReHo between the two groups were also calculated. Then correlation analyses were used to estimate the possible association between functional alterations and CSF β‐amyloid (Aβ1‐42.) and tau.Result: Multiple inter‐ and intra‐network functional connections were altered in AD patients compared to the Non ADCI group. In the AD group, ALFF decreased in the right Superior Frontal Gyrus, Middle Frontal Gyrus, left superior temporal gyrus. and increased in the right cerebellum anterior lobe, and caudate nucleus as compared to Non‐AD CI group (p < 0.001). In addition, ReHo decreased in the right insula and left middle temporal gyrus (p < 0.001). Dynamic fluctuations of CSF Tau were observed to be associated with changes in FC between VN and PCC, FC of SMN, as well as the altered ReHo in the right insula and left middle temporal gyrus. Compared the AD group with the non‐AD CI group, the aforementioned altered functional brain connectivity, with the exception of FC in the PCC and VN, was significantly associated with a decrease in CSF Aβ1‐42.Conclusion: AD patients have exhibited functional changes in more than one brain region. These changes are linked to the variations of Tau protein and Aβ1‐42 in CSF, with Aβ1‐42 having a particularly large impact on brain network function. From an imaging standpoint, this study validated the impact of pathological changes on brain function in AD.
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S2) , e084078
Open AccessCorrelation between alterations in resting‐state functional alterations of brain and cerebrospinal fluid pathological markers in patients with Alzheimer's disease
Background: The aim of this study was to explore the correlation between brain functional alterations and cerebrospinal fluid (CSF) pathological biomarkers in Alzheimer's disease (AD) patients.Method: A total of 39 individuals were recruited, including 23 AD patients and 16 control subjects. All subjects underwent a battery of neuropsychological examinations, CSF measurement and multimodal magnetic resonance imaging scans. Independent component analysis was used to investigate the variations of functional connectivity (FC) between the two groups by utilizing the resting‐sate functional MRI (RS‐fMRI) data. Differences in ALFF and ReHo between the two groups were also calculated. Then correlation analyses were used to estimate the possible association between functional alterations and CSF β‐amyloid (Aβ1‐42.) and tau.Result: Multiple inter‐ and intra‐network functional connections were altered in AD patients compared to the Non ADCI group. In the AD group, ALFF decreased in the right Superior Frontal Gyrus, Middle Frontal Gyrus, left superior temporal gyrus. and increased in the right cerebellum anterior lobe, and caudate nucleus as compared to Non‐AD CI group (p < 0.001). In addition, ReHo decreased in the right insula and left middle temporal gyrus (p < 0.001). Dynamic fluctuations of CSF Tau were observed to be associated with changes in FC between VN and PCC, FC of SMN, as well as the altered ReHo in the right insula and left middle temporal gyrus. Compared the AD group with the non‐AD CI group, the aforementioned altered functional brain connectivity, with the exception of FC in the PCC and VN, was significantly associated with a decrease in CSF Aβ1‐42.Conclusion: AD patients have exhibited functional changes in more than one brain region. These changes are linked to the variations of Tau protein and Aβ1‐42 in CSF, with Aβ1‐42 having a particularly large impact on brain network function. From an imaging standpoint, this study validated the impact of pathological changes on brain function in AD.
- 1 August 2024
- Published by Springer Nature in Chinese Journal of Academic Radiology
- Vol. 7 (3) , 264-276
Module-level structural and functional alternations in amnestic mild cognitive impairment
- 1 August 2024
- Published by Springer Nature in Chinese Journal of Academic Radiology
- Vol. 7 (3) , 264-276
Module-level structural and functional alternations in amnestic mild cognitive impairment